MONTGOMERY, ALA. (Jan. 25, 2017) – Beasley Allen lawyer Danielle Ward Mason has been appointed to the Plaintiffs’ Steering Committee (PSC) for consolidated multidistrict litigation (MDL) pending in New Jersey federal court concerning Invokana’s link to kidney damage and diabetic ketoacidosis.
The lawsuits allege Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, failed to properly test the type 2 diabetes drug and warn consumers, health care professionals and the medical community of the risks and consequences of using it. U.S. District Judge Brian R. Martinotti was appointed by the Judicial Panel on Multidistrict Litigation to preside over the MDL, which consolidated 55 cases from across the United States.
One of a number of serious side effects associated with the drug, diabetic ketoacidosis (DKA) is a type of acidosis that develops when insulin levels are too low or during prolonged fasting. Complications of DKA include difficulty breathing, nausea, vomiting, abdominal pain, confusion and unusual fatigue or sleepiness. The condition can result in a diabetic coma, extended hospitalization and even death.
In a Diabetes Care Study published in September of 2015, Invokana was associated with a much higher risk of DKA than other medications of its kind. From March of 2013, when Invokana was first approved, to October of 2015, the FDA received reports of 101 confirmable cases of acute kidney injury, some requiring hospitalization and dialysis. On June 14, 2016, the FDA revised the warnings for medications like Invokana to include information about acute kidney injury, specifically kidney failure.
Ward is Beasley Allen’s lead attorney for Invokana litigation and has been with the firm since 2009. In 2015, she was named a Principal attorney, becoming the first African-American woman at the firm to achieve that status. In addition to her work with Invokana, she is a member of the talcum powder litigation team.